Home LiteratureArticle Details
PMID: 16461914 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Core domain interactions in full-length p53 in solution.

Veprintsev DB, Freund SM, Andreeva A, Rutledge SE, Tidow H, Cañadillas JM, Blair CM, Fersht AR

Abstract

The tumor suppressor p53 consists of four 393-residue chains, each of which has two natively unfolded (N- and C-terminal) and two folded (core and tetramerization) domains. Their structural organization is poorly characterized as the protein tends to aggregate, has defied crystallization, and is at the limits of NMR studies. We first stabilized the protein by mutation to make it more suitable for extended study and then acquired NMR spectra on full-length protein and various combinations of shorter domain constructs. The NMR spectrum (15N,1H transverse relaxation optimized spectroscopy) of full-length p53 was close to that expected from the sum of the spectra of isolated individual domains. However, patterns of changes in chemical shifts revealed unexpected interactions between the core domains. We used the NMR data as constraints in docking algorithms and found a previously uncharacterized self-complementary surface for the association of core domains into dimers within the tetrameric complex. Binding to DNA requires about a 70 degrees rotation to break those subunit interactions and form the known protein:protein interface in the p53-DNA complex. We verified the interactions by the effects of mutation on DNA binding. Spectroscopic, biophysical, and mutational data conspired to give a picture of the p53 tetramer as a dimer of loosely tethered core dimers of appropriate symmetry to be poised to bind target DNA.

MeSH Terms
Crystallography DNA/chemistry Dimerization Humans Mutagenesis Protein Structure, Tertiary Solutions/chemistry Tumor Suppressor Protein p53/chemistry,genetics
Chemicals
Solutions Tumor Suppressor Protein p53 DNA
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Veprintsev Dmitry B
Medical Research Council Centre for Protein Engineering, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, United Kingdom.
Freund Stefan M V
Andreeva Antonina
Rutledge Stacey E
Tidow Henning
Cañadillas José Manuel Pérez
Blair Caroline M
Fersht Alan R
References (33)
33 references, click to expand
  1. Local structural elements in the mostly unstructured transcriptional activation domain of human p53.
    J Biol Chem. 2000 Sep 22;275(38):29426-32 PMID: 10884388
  2. The N-terminal domain of p53 is natively unfolded.
    J Mol Biol. 2003 Oct 3;332(5):1131-41 PMID: 14499615
  3. Assignment of 1H(N), 15N, 13C(alpha), 13CO and 13C(beta) resonances in a 67 kDa p53 dimer using 4D-TROSY NMR spectroscopy.
    J Biomol NMR. 2000 Oct;18(2):173-6 PMID: 11101222
  4. Modeling multi-component protein-DNA complexes: the role of bending and dimerization in the complex of p53 dimers with DNA.
    Protein Eng. 2001 Apr;14(4):233-43 PMID: 11391015
  5. The C-terminus of p53: the more you learn the less you know.
    Nat Struct Biol. 2001 Sep;8(9):730-2 PMID: 11524665
  6. Latent and active p53 are identical in conformation.
    Nat Struct Biol. 2001 Sep;8(9):756-60 PMID: 11524676
  7. NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA.
    J Biol Chem. 2001 Dec 28;276(52):49020-7 PMID: 11606582
  8. Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding.
    J Mol Biol. 2002 May 31;319(2):351-8 PMID: 12051912
  9. Live or let die: the cell's response to p53.
    Nat Rev Cancer. 2002 Aug;2(8):594-604 PMID: 12154352
  10. A graph-theory algorithm for rapid protein side-chain prediction.
    Protein Sci. 2003 Sep;12(9):2001-14 PMID: 12930999
  11. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations.
    J Biol Chem. 2004 Jan 9;279(2):1291-6 PMID: 14534297
  12. NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells.
    Biochemistry. 2004 Feb 24;43(7):1854-61 PMID: 14967026
  13. Cooperative binding of tetrameric p53 to DNA.
    J Mol Biol. 2004 Aug 27;341(5):1145-59 PMID: 15321712
  14. Regulation of DNA binding of p53 by its C-terminal domain.
    J Mol Biol. 2004 Sep 17;342(3):801-11 PMID: 15342238
  15. Presence of a potent transcription activating sequence in the p53 protein.
    Science. 1990 Aug 31;249(4972):1046-9 PMID: 2144363
  16. A transcriptionally active DNA-binding site for human p53 protein complexes.
    Mol Cell Biol. 1992 Jun;12(6):2866-71 PMID: 1588974
  17. Definition of a consensus binding site for p53.
    Nat Genet. 1992 Apr;1(1):45-9 PMID: 1301998
  18. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
    Science. 1994 Jul 15;265(5170):346-55 PMID: 8023157
  19. Solution structure of the tetrameric minimum transforming domain of p53.
    Nat Struct Biol. 1994 Dec;1(12):877-90 PMID: 7773777
  20. Refined solution structure of the oligomerization domain of the tumour suppressor p53.
    Nat Struct Biol. 1995 Apr;2(4):321-33 PMID: 7796267
  21. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels.
    J Mol Biol. 1996 Jul 19;260(3):289-98 PMID: 8757792
  22. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Science. 1996 Nov 8;274(5289):948-53 PMID: 8875929
  23. Architectural accommodation in the complex of four p53 DNA binding domain peptides with the p21/waf1/cip1 DNA response element.
    J Biol Chem. 1997 Jun 6;272(23):14830-41 PMID: 9169452
  24. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53.
    Biochemistry. 1997 Aug 19;36(33):10117-24 PMID: 9254608
  25. Modelling protein docking using shape complementarity, electrostatics and biochemical information.
    J Mol Biol. 1997 Sep 12;272(1):106-20 PMID: 9299341
  26. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein.
    J Med Chem. 1997 Sep 26;40(20):3144-50 PMID: 9379433
  27. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution.
    Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12366-71 PMID: 9356455
  28. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding.
    Proc Natl Acad Sci U S A. 1998 May 26;95(11):6079-84 PMID: 9600920
  29. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability.
    Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14675-80 PMID: 9843948
  30. Use of pair potentials across protein interfaces in screening predicted docked complexes.
    Proteins. 1999 May 15;35(3):364-73 PMID: 10328272
  31. Hot-spot mutants of p53 core domain evince characteristic local structural changes.
    Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8438-42 PMID: 10411893
  32. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations.
    J Biol Chem. 2005 Apr 22;280(16):16030-7 PMID: 15703170
  33. Surfing the p53 network.
    Nature. 2000 Nov 16;408(6810):307-10 PMID: 11099028
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2006-02-14
Epub
2006-00-06
Pages
2115-9
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC1413758
Subset
IM
Grants
Medical Research Council · G0100305 · United Kingdom
Medical Research Council · MC_U105474168 · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com